High-Frequency Canonical Wnt Activation in Multiple Sarcoma Subtypes Drives Proliferation through a TCF/β-Catenin Target Gene, CDC25A

Cancer Cell

Volumn 19, Issue 5, 2011, Pages 601-612

  Vijayakumar, Sapna ^a   Liu, Guizhong ^a   Rus, Ioana A ^a   Yao, Shen ^a   Chen, Yan ^a   Akiri, Gal ^a   Grumolato, Luca ^a   Aaronson, Stuart A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; LIGAND; PROTEIN TYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR; WNT PROTEIN;

ADENOMATOUS POLYP; ANGIOSARCOMA; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURFACE; CHONDROSARCOMA; DOWN REGULATION; EWING SARCOMA; FIBROSARCOMA; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEIOMYOSARCOMA; LIPOSARCOMA; MESENCHYMAL STEM CELL; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA;

EID: 79955964176     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.03.010     Document Type: Article

References (67)

1. Akiri G., Cherian M.M., Vijayakumar S., Liu G., Bafico A., Aaronson S.A. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 2009, 28:2163-2172.
2. Bafico A., Gazit A., Wu-Morgan S.S., Yaniv A., Aaronson S.A. Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts. Oncogene 1998, 16:2819-2825.
3. Bafico A., Gazit A., Pramila T., Finch P.W., Yaniv A., Aaronson S.A. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J. Biol. Chem. 1999, 274:16180-16187.
4. Bafico A., Liu G., Yaniv A., Gazit A., Aaronson S.A. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 2001, 3:683-686.
5. Bafico A., Liu G., Goldin L., Harris V., Aaronson S.A. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004, 6:497-506.
6. Bienz M., Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000, 103:311-320.
7. Boutros R., Lobjois V., Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat. Rev. Cancer 2007, 7:495-507.
8. Cai Y., Mohseny A.B., Karperien M., Hogendoorn P.C., Zhou G., Cleton-Jansen A.M. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J. Pathol. 2010, 220:24-33.
9. Chen M.S., Hurov J., White L.S., Woodford-Thomas T., Piwnica-Worms H. Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol. Cell. Biol. 2001, 21:3853-3861.
10. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
11. Doghman M., Cazareth J., Lalli E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J. Clin. Endocrinol. Metab. 2008, 93:3222-3225.
12. Ferguson A.M., White L.S., Donovan P.J., Piwnica-Worms H. Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol. Cell. Biol. 2005, 25:2853-2860.
13. Finch A.J., Soucek L., Junttila M.R., Swigart L.B., Evan G.I. Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation. Mol. Cell. Biol. 2009, 29:5306-5315.
14. Galaktionov K., Chen X., Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996, 382:511-517.
15. Giles R.H., van Es J.H., Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 2003, 1653:1-24.
16. Hanahan D., Weinberg R.A. The Hallmarks of Cancer. Cell 2000, 100:57-70.
17. Hartmann C. A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol. 2006, 16:151-158.
18. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
19. He X., Saint-Jeannet J.P., Wang Y., Nathans J., Dawid I., Varmus H. A member of the Frizzled protein family mediating axis induction by Wnt- 5A. Science 1997, 275:1652-1654.
20. Helman L.J., Meltzer P. Mechanisms of sarcoma development. Nat. Rev. Cancer 2003, 3:685-694.
21. Hovanes K., Li T.W., Munguia J.E., Truong T., Milovanovic T., Lawrence Marsh J., Holcombe R.F., Waterman M.L. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat. Genet. 2001, 28:53-57.
22. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., Charlat O., Wiellette E., Zhang Y., Wiessner S., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
23. Jaiswal R.K., Jaiswal N., Bruder S.P., Mbalaviele G., Marshak D.R., Pittenger M.F. Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. J. Biol. Chem. 2000, 275:9645-9652.
24. Jemal A., Thun M.J., Ries L.A., Howe H.L., Weir H.K., Center M.M., Ward E., Wu X.C., Eheman C., Anderson R., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J. Natl. Cancer Inst. 2008, 100:1672-1694.
25. Jho E.H., Zhang T., Domon C., Joo C.K., Freund J.N., Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol. 2002, 22:1172-1183.
26. Jung C.K., Jung J.H., Lee A., Lee Y.S., Choi Y.J., Yoon S.K., Lee K.Y. Diagnostic use of nuclear [beta]-catenin expression for the assessment of endometrial stromal tumors. Mod. Pathol. 2008, 21:756-763.
27. Kang T., Wei Y., Honaker Y., Yamaguchi H., Appella E., Hung M.C., Piwnica-Worms H. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 2008, 13:36-47.
28. Kansara M., Thomas D.M. Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007, 26:1-18.
29. Kansara M., Tsang M., Kodjabachian L., Sims N.A., Trivett M.K., Ehrich M., Dobrovic A., Slavin J., Choong P.F., Simmons P.J., et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 2009, 119:837-851.
30. Khan Z., Vijayakumar S., de la Torre T.V., Rotolo S., Bafico A. Analysis of endogenous LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its receptor. Mol. Cell. Biol. 2007, 27:7291-7301.
31. Kildal W., Pradhan M., Abeler V.M., Kristensen G.B., Danielsen H.E. [beta]-Catenin expression in uterine sarcomas and its relation to clinicopathological parameters. Eur. J. Cancer 2009, 45:2412-2417.
32. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
33. Leung J.Y., Kolligs F.T., Wu R., Zhai Y., Kuick R., Hanash S., Cho K.R., Fearon E.R. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J. Biol. Chem. 2002, 277:21657-21665.
34. Li X., Liu P., Liu W., Maye P., Zhang J., Zhang Y., Hurley M., Guo C., Boskey A., Sun L., et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat. Genet. 2005, 37:945-952.
35. Liu G., Vijayakumar S., Grumolato L., Arroyave R., Qiao H., Akiri G., Aaronson S.A. Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells. J. Cell Biol. 2009, 185:67-75.
36. MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 2009, 17:9-26.
37. Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A., Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001, 411:321-325.
38. Mateyak M.K., Obaya A.J., Sedivy J.M. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol. Cell. Biol. 1999, 19:4672-4683.
39. Matushansky I., Hernando E., Socci N.D., Mills J.E., Matos T.A., Edgar M.A., Singer S., Maki R.G., Cordon-Cardo C. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J. Clin. Invest. 2007, 117:3248-3257.
40. Miyagawa Y., Okita H., Nakaijima H., Horiuchi Y., Sato B., Taguchi T., Toyoda M., Katagiri Y.U., Fujimoto J., Hata J., et al. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol. Cell. Biol. 2008, 28:2125-2137.
41. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
42. Ng T.L., Gown A.M., Barry T.S., Cheang M.C., Chan A.K., Turbin D.A., Hsu F.D., West R.B., Nielsen T.O. Nuclear beta-catenin in mesenchymal tumors. Mod. Pathol. 2005, 18:68-74.
43. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
44. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim. Biophys. Acta 1997, 1332:F127-F147.
45. Polakis P. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 1999, 9:15-21.
46. Polakis P. Wnt signaling and cancer. Genes Dev. 2000, 14:1837-1851.
47. Radtke F., Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005, 307:1904-1909.
48. Rattner A., Hsieh J.C., Smallwood P.M., Gilbert D.J., Copeland N.G., Jenkins N.A., Nathans J. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc. Natl. Acad. Sci. USA 1997, 94:2859-2863.
49. Ray D., Terao Y., Fuhrken P.G., Ma Z.Q., DeMayo F.J., Christov K., Heerema N.A., Franks R., Tsai S.Y., Papoutsakis E.T., Kiyokawa H. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 2007, 67:984-991.
50. Ray D., Terao Y., Nimbalkar D., Hirai H., Osmundson E.C., Zou X., Franks R., Christov K., Kiyokawa H. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res. 2007, 67:6605-6611.
51. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
52. Roose J., Huls G., van Beest M., Moerer P., van der Horn K., Goldschmeding R., Logtenberg T., Clevers H. Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science 1999, 285:1923-1926.
53. Ross S.E., Hemati N., Longo K.A., Bennett C.N., Lucas P.C., Erickson R.L., MacDougald O.A. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
54. Sansom O.J., Meniel V.S., Muncan V., Phesse T.J., Wilkins J.A., Reed K.R., Vass J.K., Athineos D., Clevers H., Clarke A.R. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446:676-679.
55. Semenov M.V., Tamai K., Brott B.K., Kuhl M., Sokol S., He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr. Biol. 2001, 11:951-961.
56. Siddappa R., Martens A., Doorn J., Leusink A., Olivo C., Licht R., van Rijn L., Gaspar C., Fodde R., Janssen F., et al. cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo. Proc. Natl. Acad. Sci. USA 2008, 105:7281-7286.
57. Skubitz K.M., D'Adamo D.R. Sarcoma. Mayo Clin. Proc. 2007, 82:1409-1432.
58. Suzuki H., Watkins D.N., Jair K.W., Schuebel K.E., Markowitz S.D., Dong Chen W., Pretlow T.P., Yang B., Akiyama Y., Van Engeland M., et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 2004, 36:417-422.
59. Tamai K., Semenov M., Kato Y., Spokony R., Liu C., Katsuyama Y., Hess F., Saint-Jeannet J.P., He X. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000, 407:530-535.
60. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
61. Tezuka K., Yasuda M., Watanabe N., Morimura N., Kuroda K., Miyatani S., Hozumi N. Stimulation of osteoblastic cell differentiation by Notch. J. Bone Miner. Res. 2002, 17:231-239.
62. Tirode F., Laud-Duval K., Prieur A., Delorme B., Charbord P., Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007, 11:421-429.
63. van Amerongen R., Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009, 136:3205-3214.
64. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
65. Vigo E., Muller H., Prosperini E., Hateboer G., Cartwright P., Moroni M.C., Helin K. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol. Cell. Biol. 1999, 19:6379-6395.
66. Wu W., Glinka A., Delius H., Niehrs C. Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr. Biol. 2000, 10:1611-1614.
67. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.